Oral Bisphosphonates and Upper Gastrointestinal Tract Problems: What Is the Evidence?
- 31 October 2002
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 77 (10) , 1031-1043
- https://doi.org/10.4065/77.10.1031
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- Upper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical TrialsMayo Clinic Proceedings, 2002
- RisedronateDrugs, 2001
- Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptomsClinical Therapeutics, 2000
- Preventing Fractures in Postmenopausal Women with OsteoporosisDrugs & Aging, 2000
- Alendronate for the Treatment of Osteoporosis in MenNew England Journal of Medicine, 2000
- Bisphosphonates in osteoporosis: recent clinical experienceExpert Opinion on Pharmacotherapy, 2000
- AlendronateDrugs, 1997
- The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding studyBone, 1996
- ClodronateDrugs, 1994
- Effects of one-year cyclical treatment with clodronate on postmenopausal bone lossBone, 1993